SCHEMBL1633256

SCHEMBL1633256

N#Cc1ccc(Nc2ncc3cccc(OC4CCNCC4)c3n2)cc1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 5/20 0.67
JAK1 P23458 5/20 0.67
TYK2 P29597 5/20 0.67
JAK3 P52333 5/20 0.67
TNIK Q9UKE5 1/20 0.54
CHEK1 O14757 7/20 0.47
SYK P43405 2/20 0.45
ALK Q9UM73 1/20 0.42
MAOB P27338 1/20 0.42
GRM5 P41594 1/20 0.42
FLT3 P36888 1/20 0.41
CDK1 P06493 1/20 0.41
CDK4 P11802 1/20 0.41
CCNB1 P14635 1/20 0.41
CCND1 P24385 1/20 0.41
CCNE1 P24864 1/20 0.41
CDK2 P24941 1/20 0.41
IGF1R P08069 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12724448 0.88 JAK2 (0.71) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1635098 0.88 JAK2 (0.74) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1633815 0.84 JAK2 (0.54) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1633545 0.84 JAK2 (0.65) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1633224 0.84 JAK2 (0.65) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1634192 0.83 JAK2 (0.64) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1634409 0.81 JAK2 (0.65) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1632625 0.81 JAK2 (0.62) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1634109 0.81 JAK2 (0.67) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1632720 0.81 JAK2 (0.64) JAK2JAK1TYK2JAK3TNIK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed